CLNN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

37.86K

-58.4%

-0.553

-66.89%

71.67K

-11.52%

-0.517

+474.08%

71.67K

+165.44%

-0.583

-25.21%

Estimates Revision

The market is revising Downward the revenue expectations for Clene Inc. (CLNN) for FY2025, with the revenue forecasts being adjusted by -32.83% over the past three months. During the same period, the stock price has changed by -32.26%.

Revenue Estimates for FY2025

Revise Downward

-32.83%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+10.05%

In Past 3 Month

Stock Price

Go Down

-32.26%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast CLNN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLNN is 28.40 USD with a low forecast of 20.00 USD and a high forecast of 31.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

20.00

Averages

28.40

High

31.00

Current: 0.000

Low

20.00

Averages

28.40

High

31.00

Maxim

Naz Rahman

Buy

maintain

$20 -> $30

2025-12-03

Reason

Maxim

Naz Rahman

Price Target

$20 -> $30

2025-12-03

maintain

Buy

Reason

Maxim analyst Naz Rahman raised the firm's price target on Clene to $30 from $20 and keeps a Buy rating on the shares after the company and its wholly owned subsidiary Clene Nanomedicine announced completion of the FDA-recommended biomarker analyses for CNM-Au8 in people living with ALS. The results demonstrate statistically significant reductions in both neurofilament light, NfL, and glial fibrillary acidic protein, GFAP, which "clears way" for an NDA filing, the analyst says.

Benchmark

Buy

downgrade

$33 -> $31

2025-09-10

Reason

Benchmark

Price Target

$33 -> $31

2025-09-10

downgrade

Buy

Reason

Benchmark lowered the firm's price target on Clene to $31 from $33 and keeps a Buy rating on the shares. Having obtained agreement from the FDA regarding the statistical analysis plan, Clene continues to work toward an anticipated NDA submission in Q4 for CNM-Au-8 in the treatment of ALS, the analyst noted while updating the firm's model.

Canaccord

Buy

downgrade

$83 -> $48

2025-08-18

Reason

Canaccord

Price Target

$83 -> $48

2025-08-18

downgrade

Buy

Reason

Canaccord lowered the firm's price target on Clene to $48 from $83 and keeps a Buy rating on the shares. The firm updated its model following Q2 results but admits clarity from the FDA on its ability to file for accelerated approval or not for its ALS and Ms drugs are the key. They now include contributions from ALS and MS at probabilities of approval of 33% and 20%, respectively in their model.

Jones Trading

Justin Walsh

Strong Buy

Initiates

$30

2025-04-23

Reason

Jones Trading

Justin Walsh

Price Target

$30

2025-04-23

Initiates

Strong Buy

Reason

JonesResearch analyst Justin Walsh initiated coverage of Clene with a Buy rating and $30 price target. Clene is a clinical-stage pharmaceutical company developing nanothechnology therapeutics for the treatment of central nervous system disorders, the analyst tells investors in a research note. The firm says the company's clinical setbacks in amyotrophic lateral sclerosis "are not the end of the story." The market has written off potential accelerated approval prematurely, contends JonesResearch.

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$31

2025-04-08

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$31

2025-04-08

Reiterates

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$23

2025-04-08

Reason

D. Boral Capital

Jason Kolbert

Price Target

$23

2025-04-08

Maintains

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Clene Inc (CLNN.O) is -2.49, compared to its 5-year average forward P/E of -5.02. For a more detailed relative valuation and DCF analysis to assess Clene Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.02

Current PE

-2.49

Overvalued PE

1.60

Undervalued PE

-11.63

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.61

Current EV/EBITDA

-2.06

Overvalued EV/EBITDA

-0.46

Undervalued EV/EBITDA

-2.77

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

450.37

Current PS

235.77

Overvalued PS

928.58

Undervalued PS

-27.84

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CLNN News & Events

Events Timeline

No data

News

8.5

01-09Globenewswire

Clene Inc. Secures $28 Million Financing to Advance ALS Drug Development

5.0

2025-12-18Yahoo Finance

Clene Insider Offloads Shares Valued at $1,725,735, Per Recent SEC Filing

1.0

2025-12-10Globenewswire

88th Emerging Growth Conference Scheduled for December 10-11, 2025

People Also Watch

Frequently Asked Questions

What is Clene Inc (CLNN) stock price today?

The current price of CLNN is 6.395 USD — it has increased 7.12 % in the last trading day.

What is Clene Inc (CLNN)'s business?

Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis. It specializes in the discovery, development, and commercialization of clean-surfaced nanotechnology (CSN) therapeutics. CNM-Au8, the lead asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. CNM-Au8’s mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is a broad-spectrum antiviral, antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions under development to treat infectious disease and to provide immune support for symptom resolution. Its CNM-AgZn17 is a gel polymer suspension of Zn2+ and Ag+ under development for the treatment of infectious diseases and to support wound healing.

What is the price predicton of CLNN Stock?

What is Clene Inc (CLNN)'s revenue for the last quarter?

Clene Inc revenue for the last quarter amounts to 15.00K USD, decreased -82.76 % YoY.

What is Clene Inc (CLNN)'s earnings per share (EPS) for the last quarter?

Clene Inc. EPS for the last quarter amounts to -0.85 USD, decreased -30.33 % YoY.

What changes have occurred in the market's expectations for Clene Inc (CLNN)'s fundamentals?

How many employees does Clene Inc (CLNN). have?

Clene Inc (CLNN) has 75 emplpoyees as of January 10 2026.

What is Clene Inc (CLNN) market cap?

Today CLNN has the market capitalization of 66.09M USD.